Purification and expression of a processing protease on β-alanine-oxoglutarate aminotransferase from rat liver mitochondria  by Ohyama, Tomoko et al.
FEBS 28681 FEBS Letters 572 (2004) 251–255Puriﬁcation and expression of a processing protease on
b-alanine-oxoglutarate aminotransferase from rat liver mitochondriaTomoko Ohyamaa,*, Koichi Matsudaa, Hideyuki Tachibanaa, Shigeko Fujimoto Sakataa,
Masataka Morib, Masahisa Horiuchic, Nanaya Tamakia
aFaculty of Nutrition and High Technology Research Center, Kobe-Gakuin University, Arise 518, Ikawadani-cho, Nishi-ku, Kobe 651-2180, Japan
bDepartment of Molecular Genetics, Kumamoto University School of Medicine, Kumamoto, Japan
cLaboratory for Neuroanatomy, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan
Received 3 May 2004; revised 10 July 2004; accepted 19 July 2004
Available online 28 July 2004
Edited by Judit OvadiAbstract GABA[arrow beta]AlaAT convertase is an endopep-
tidase that processes brain-type 4-aminobutyrate aminotransferase
(GABA AT; EC 2.6.1.19) to liver-type b-alanine-oxoglutarate
aminotransferase (b-AlaAT I) in rats. Its molecular mass was
180 kDa as determined by gel ﬁltration. A subunit molecular
mass of 97 652 Da was measured using MALDI-TOF MS. The
N-terminal sequence of the puriﬁed GABA[arrow beta]AlaAT
convertase was SRVEVSKVLILGSGGLSIGQAGEFDYSGS-
QAV- and was identical to residues 418–449 of carbamoyl-
phosphate synthetase I (CPS I; EC 1.2.1.27) puriﬁed from rat
liver. The subunit molecular mass and the N-terminal amino acid
sequence suggested that GABA[arrow beta]AlaAT convertase
was the 418–1305 peptide of CPS I. An expression vector
containing the coding region of the 418–1305 peptide of rat CPS
I was transfected into NIH3T3 cells and the extract of the cells
showed GABA[arrow beta]AlaAT convertase activity.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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synthetase1. Introduction
b-Alanine-oxoglutarate aminotransferase (b-AlaAT I) cata-
lyzes the transamination of b-alanine, which is mainly formed
in liver cytosol by the reductive degradation of uracil via di-
hydrouracil and N-carbamoyl-b-alanine [1–3], and transported
into mitochondria [4]: where b-alanine is further metabolized
to malonate semialdehyde by b-AlaAT I or D-3-aminoisobu-
tyrate-pyruvate aminotransferase (b-AlaAT II; EC 2.6.1.40) in
the mitochondrial matrix [4,5].* Corresponding author. Fax: +81-78974-5842.
E-mail address: f9blh801@nutr.kobegakuin.ac.jp (T. Ohyama).
Abbreviations: GABA, 4-aminobutyrate; b-AlaAT I, b-alanine-oxo-
glutarate aminotransferase; GABA AT, GABA aminotransferase;
b-AlaAT II, (R)-3-amino-2-methylpropionate-pyruvate aminotrans-
ferase [(R)-b-aminoisobutyrate-pyruvate aminotransferase]; pre-
GABA AT, precursor of GABA AT; CPS I, carbamoyl-phosphate
synthetase I; PMSF, phenylmethylsulfonylﬂuoride; PCR, polymerase
chain reaction
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doi:10.1016/j.febslet.2004.07.043b-AlaAT I puriﬁed from rat liver also catalyzes the trans-
amination of 4-aminobutyrate (GABA) [6] and L-b-amino-
isobutyrate [7] in addition to b-alanine, while b-AlaAT II is
not active for GABA [8]. It is well known that GABA is a
major inhibitory transmitter in many invertebrate systems and
also in the vertebrate central nervous system. Enzyme activity
of b-AlaAT I is mainly distributed in the mitochondrial matrix
of the brain [9], liver [4], and kidney [5] in rats. The immu-
nological and kinetic properties show that b-AlaAT I from rat
liver closely resembles those of GABA aminotransferase
(GABA AT) from the rat brain [6]. Rat liver b-AlaAT I
mRNA and rat brain GABA AT mRNA are transcripts from
the same gene [10]. However, the N-terminal amino acid of rat
liver b-AlaAT I is Val [6], while that of rat brain GABA AT
has been identiﬁed as I1e [11] by the dansyl method. The
amino acid sequence predicted from rat liver cDNA suggests
that the precursor to b-AlaAT I (pre-GABA AT) consists of a
liver-type mature enzyme of 466 amino acid residues, with 34
residues attributed to the leader peptide. The mature form of
GABA AT from the brain has an ISQAAAK-peptide addi-
tional to the N-terminus sequence of liver-type mature-b-
AlaAT I [10] (Scheme 1).
The liver-type mature enzyme and the brain-type mature
enzyme were named mature-b-AlaAT I and mature-GABA
AT, respectively. Brain-type GABA AT is cleaved to liver-type
b-AlaAT I protein when incubated with fresh mitochondrial
extract from rat liver [10]. These results suggest the existence of
an enzyme, which converts the brain-type mature-GABA AT
to the liver-type mature-b-AlaAT I. This paper describes the
puriﬁcation of the enzyme GABA[arrow beta]AlaAT conver-
tase from rat liver mitochondria.2. Materials and Methods
2.1. Materials
All reagents were of analytical grade and were purchased from
Nacalai Tesque (Kyoto, Japan). DEAE–Sepharose CL-6B and Seph-
acryl S-200 were obtained from Amersham Biosciences (Uppsala,
Sweden). Hydroxyapatite was obtained from the Seikagaku Corpo-
ration (Tokyo, Japan) Cibacron blue F3G-A-Sepharose 4B was pre-
pared by binding Cibacron blue F3G-A to Sepharose 4B according to
Rinderknecht et al. [12] and was used to remove adenine nucleotide
speciﬁc binding proteins. The Escherichia coli strain TOP 10, pSE420
expression vector and the polymerase chain reaction (PCR) primers
were obtained from Invitrogen Corp. (CA, USA). Restriction enzymesation of European Biochemical Societies.
Scheme 1. Processing of rat liver b-AlaAT I. Alignment of the N-terminal amino acid sequence of GABA AT from rats. Single arrow (") indicates the
putative processing site cleaved by mitochondrial processing peptidase. Double arrow (*) indicates the processing site of rat liver GABA[arrow
beta]AlaAT convertase.
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QuickChange site-directed mutagenesis kit was obtained from
STRATAGENE (CA, USA), TransFast Transfection Reagent and
pCI-neo expression vector were obtained from Promega Corp. (WI,
USA). NIH3T3 cells were obtained from Riken (Tsukuba, Japan). The
molecular mass markers for SDS–PAGE were a product of Invitrogen
Corp. (CA, USA).
2.2. Preparation of mitochondrial extract
Fresh livers (40 g) from male Wistar ST strain rats were ho-
mogenized using Potter-Elvejem homogenizer in 10 vol. (w/v) of
0.25 M sucrose in respect to the original liver mass. The homoge-
nate was centrifuged for 10 min at 500g. The supernatant was
centrifuged again for 10 min at 8000g to obtain pellets of mito-
chondria. The mitochondria were suspended in a minimum volume
of 0.25 M sucrose. They were then put in a tube with a prepared
sucrose density gradient from 1.15 to 1.24 g/ml and centrifuged for
180 min at 82 000g. After centrifugation, the mitochondrial frac-
tions were recovered and resuspended in 0.25 M sucrose containing
10 mM potassium phosphate, pH 7.5, 1 mM EDTA, and 2 mM
2-mercaptoethanol. The mitochondrial suspension was sonicated
with Microson, Model XL2000 (Misonix Incorporated, New
York, USA). The sonicated suspension was centrifuged for 15 min
at 10 000g. The supernatant was used as the mitochondrial
extract.
2.3. Preparation of mature-GABA AT from rat brain
Mature-GABA AT from rat brain was puriﬁed according to the
methods previously described [6].
2.4. Assay of GABA[arrow beta]AlaAT convertase activity
GABA[arrow beta]AlaAT convertase activity was determined by
measuring the rate of conversion from mature-GABA AT to the ma-
ture-b-AlaAT I liver form. The standard reaction mixture contained
0.3 lg of puriﬁed mature-GABA AT, 10 mM potassium phosphate,
pH 7.0, containing 0.5 mM EDTA and 2 mM 2-mercaptoethanol in a
ﬁnal volume of 12 ll. The incubation was carried out for 3 h at 25 C.
The reaction was terminated with the addition of 2% SDS, then ana-
lyzed using SDS–PAGE (7.5% gel). The immunoblot analysis was
conducted by the method of Towbin et al. [13]. Rabbit polyclonal
antibody against rat liver b-AlaAT I has been previously prepared [6].
The densities of bands corresponding to mature-GABA AT and ma-
ture-b-AlaAT I were determined using an image analyzer (Fujiﬁlm
FLA-2000, Tokyo, Japan). One unit of enzyme activity was deﬁned as
the amount that produced a 50% conversion of mature-GABA AT to
mature-b-AlaAT I under the standard assay conditions. The enzymeactivity was proportional with reaction time until about 90% of the
product was formed.
2.5. Puriﬁcation procedure of GABA[arrow beta]AlaAT convertase
All subsequent steps were performed at approximately 4 C. Puri-
ﬁcation was started from the mitochondrial extract from 40 g of rat
liver. The precipitate obtained at 50% ammonium sulfate saturation
was dissolved in a minimum volume of buﬀer A (10 mM potassium
phosphate, pH 7.5, containing 0.5 mM EDTA, 2 mM 2-mercap-
toethanol, and 0.1 mM phenylmethylsulfonylﬂuoride (PMSF)) and
desalted via dialysis against buﬀer A overnight at 4 C. After centri-
fugation, the supernatant was applied to a DEAE–Sepharose CL-6B
column (2.016 cm, ﬂow rate 24 ml/h) equilibrated with buﬀer A
containing 10% (v/v) glycerol. The column was washed with about 120
ml of buﬀer A and eluted with buﬀer A containing 100 mM KC1,
followed by 100–350 mM linear gradient KC1 in buﬀer A. The active
fractions were concentrated using a Centricon Plus 20 (Amicon Corp.
MA, USA). The enzyme preparation was applied to a Cibacron blue
F3G-A-Sepharose 4B column (1.58.5 cm, ﬂow rate 12 ml/h) equili-
brated with buﬀer B (10 mM potassium phosphate, pH 7.0, containing
0.5 mM EDTA, 2 mM 2-mercaptothanol, 0.1 mM PMSF, and 10% (v/
v) glycerol). GABA[arrow beta]AlaAT convertase passed through the
column with buﬀer B. The eluate was applied to a hydroxyapatite
column (1.06.4 cm, ﬂow rate 6 ml/h) equilibrated with buﬀer B,
followed by buﬀer B-buﬀer C (100 mM potassium phosphate, pH 7.0,
containing 0.5 mM EDTA, 2 mM 2-mercaptoethanol, 0.1 mM PMSF,
and 10% (v/v) glycerol) linear gradient. The active fraction was con-
centrated to about 1.0 ml using Centricon Plus 20. The enzyme was
applied to a Sephacryl S-200 column (1.560 cm, ﬂow rate 10 ml/h)
equilibrated with buﬀer C. The active fraction was concentrated to
about 1.0 ml, then stored at 4 C.
2.6. Inhibition of GABA[arrow beta]AlaAT convertase activity by an
antiserum against carbamoyl-phosphate synthetase I
Rabbit polyclonal antibody against rat liver carbamoyl-phosphate
synthetase I (CPS I) was prepared previously [14,15]. The proteins of
the rabbit serum were precipitated with 50% (NH4)2SO4 and dialyzed
in 10 mM potassium phosphate, pH 7.0. The solution was diluted with
the above buﬀer and was used as anti-CPS I.
GABA[arrow beta]AlaAT convertase (0.5 lg) was incubated with
anti-CPS I [14,15] for 1 h at 25 C. GABA AT was added to the above
reaction mixture and incubated for 3 h at 25 C.
The processing reaction was stopped by the addition of 2% SDS.
Immunoblot analysis was performed using SDS–PAGE with rabbit b-
AlaAT I antibody and the inhibition of GABA[arrow beta]AlaAT
convertase activity was analyzed.
Fig. 1. Gel electrophoresis of puriﬁed GABA[arrow beta]AlaAT
Convertase. The enzyme of each puriﬁcation step was analyzed by
polyacrylamide gel electrophoresis in the presence of 0.1% SDS and
immunoblot analysis was performed with rabbit CPS I antibody. A
Bench Mark Prestained Protein Ladder(Invitrogen) was used as the
molecular mass markers. (A) The mitochondrial extract (total protein
120 lg). (B) After DEAE–sepharose CL-6B chromatography (total
protein 100 lg). (C) After hydroxyapatite chromatography (total
protein 2 lg). (D) The puriﬁed enzyme (total protein 0.5 lg after
Sephacryl S-200 chromatography): (1) the gel was stained with Coo-
massie brilliant blue R-250; (2) the gel was immunoblotted and ana-
lyzed with CPS I antibody.
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GABA[arrow beta]AlaAT convertase (the peptide of CPS I 418–
1305) cDNA was ampliﬁed using the PCR method with the forward
primer 50-AAGAAATTCATGTCTCGAGTCGAGGTTTCCAA-30
and the reverse primer 50-AAGAATTCTTACTTAATGGCAA-
CATAGTCAGAG-30 containing EcoR I sites, respectively. The PCR-
generated fragment GABA[arrow beta]AlaAT convertase cDNA was
then cloned into the EcoR I site of pCI-neo for the mammalian cell
expression vector (pCI-neo-convertase). The constructs were trans-
fected into NIH3T3 cells using TransFast Transfection Reagent
following the manufacturer’s protocol. NIH3T3 cells were harvested
48 h after transfection using centrifugation for 2 min at 300g. The
precipitate was suspended with 200 ll of 10 mM potassium phosphate,
pH 7.0, containing 0.5 mM EDTA, 2 mM 2-mercaptoethanol, 0.1 mM
PMSF and 10% glycerol. After sonication, the suspension was cen-
trifuged for 20 min at 15 000g. The supernatant was used for the
assay of GABA[arrow beta]AlaAT convertase activity. The pCI-neo
expression vector was transfected to NIH3T3 cells as a control.
2.8. Expression of the pre- and mature-GABA ATs in E. coli
The coding region of GABA AT cDNA was ampliﬁed using the
PCR method with the forward primer 50-TAGCGGCCGCA-
TGGCCTTCTTGTTGACTAC-30 and the reverse primer 50-GAC-
TCGAGTTACTTGAAGTCTGCTAAGA-30 containing NcoI and
XhoI sites, respectively. The PCR generated fragment was then cloned
into the NcoI and XhoI sites of pSE420. The resulting plasmid pSE420-
pre-GABA AT contained the nucleotides that contributed to a 500
amino acid residue. E. coli TOP 10 strain was transformed with the
ligation mixture. pSE420-pre-GABA AT clones were selected in the
ampicillin-resistant transformants. The construction of pSE420-ma-
ture-GABA AT was performed using a QuickChange site-directed
mutagenesis kit following the manufacturer’s protocol. E. coli trans-
formed with pSE420-pre-GABA AT or pSE420-mature-GABA AT
were cultured for 48 h at 29  C, then harvested using centrifugation for
5 min at 800g [16,17]. The precipitate was washed with 10 mM
potassium phosphate, pH 7.5, containing 1.0 mM EDTA, 2 mM 2-
mercaptoethanol, and 50 lM pyridoxal phosphate, then harvested for
5 min at 800g. After sonication of the harvested cells, the suspension
was centrifuged for 20 min at 10 000g. The supernatant containing
the recombinant pre-GABA AT and mature-GABA AT was used as a
substrate of GABA[arrow beta]AlaAT convertase.
2.9. Determination of molecular masses
The subunit molecular mass of puriﬁed GABA[arrow beta]AlaAT
convertase was determined by Sephacryl S-200 chromatography with
thyroglobulin (670 kDa), gammaglobulin (158 kDa), ovalbumin (44
kDa) and myoglobin (17 kDa)as the markers. The molecular masses of
the GABA[arrow beta]AlaAT convertase, mature-GABA AT and
mature-b-AlaAT I were determined with MALDI-TOF MS, Voyager
DE-STR (Boston, MA, USA).3. Results
3.1. Puriﬁcation of GABA[arrow beta]AlaAT convertase
The puriﬁcation steps and the speciﬁc activity were shown in
Table 1. GABA[arrow beta]AlaAT convertase could be sepa-
rated from mature-b-AlaAT I, which is basally expressed in
liver, by DEAE–Sepharose chromatography. Therefore, weTable 1
Puriﬁcation of GABA[arrow beta]AlaAT convertase from rat liver
Steps Total protein (mg) Total activit
DEAE–Sepharose chromatography 13.69 53.4
Cibacron blue chromatography 1.87 21.8
Hydroxyapatite chromatography 0.20 5.3
Sephacryl S-200 chromatography 0.05 4.6
One unit of processing activity is deﬁned as the amount of enzyme that clea
condition described in Section 2.could estimate GABA[arrow beta]AlaAT convertase activity
after the DEAE–Sepharose chromatography step.
In gel electrophoresis, a GABA[arrow beta]AlaAT conver-
tase band stained with CPS I antibody was found in the rat
liver mitochondrial extract (Fig. 1A) and puriﬁed to a single
band (Fig. 1D-2). The puriﬁed GABA[arrow beta]AlaAT
convertase showed a single band stained with Coomassie
brilliant blue R-250 (Fig. 1D-l).
By comparing it with the reference proteins, the molecular
mass of the puriﬁed enzyme by Sephacryl S-200 was calculated
to be 180 kDa. The subunit molecular mass of the puriﬁed
GABA[arrow beta]AlaAT convertase was 97 kDa (Fig. 1). The
molecular mass of the puriﬁed enzyme determined by MAL-
DI-TOF MS was 97 652 Da. These ﬁndings suggest that pu-
riﬁed GABA[arrow beta]AlaAT convertase from rat liver is
organized as a dimer.
3.2. N-terminal amino acid sequence and identiﬁcation with a
segment of CPS I
The N-terminal sequence of the puriﬁed GABA[arrow be-
ta]AlaAT convertase determined by dansyl Edman methody (U) Speciﬁc activity (U/mg) Puriﬁcation (-fold) Yield (%)
3.9 1.0 100
11.7 3.0 41
26.0 6.7 9.9
92.0 23.6 8.6
ves 50% of mature-GABA AT to mature-b-AlaAT I under the assay
Fig. 2. Inhibition of GABA[arrow beta]AlaAT convertase activity by
an antibody against CPSI GABA[arrow beta]AlaAT convertase was
preincubated with buﬀer or anti CPS I serum. After the incubation,
GABA[arrow beta]AlaAT convertase activity was assayed with 0.3 lg
of puriﬁed GABA AT as substrate.
Fig. 4. Processing of GABA AT precursors. The extract from bacteria,
which expressed pre-GABA AT or mature-GABA AT, was incubated
in the presence or absence of 0.5 lg of puriﬁed GABA[arrow be-
ta]AlaAT convertase under the standard assay conditions. Immuno-
blot analysis was performed with anti-rat b-AlaAT I rabbit serum.
Lane 1, 10 lg protein of fresh extract from rat brain; lane 2, 10 lg
protein of fresh extract from rat liver; lanes 3 and 4, 15 lg crude extract
of pre-GABA AT; lanes 5 and 6, 15 lg crude extract of recombinant
mature-GABA AT; lane 7, 30 lg crude extract of the E. coli strain
TOP 10. The bands of low molecular mass in lanes 3–7 are non-speciﬁc
bands, which are derived from the E. coli strain TOP 10.
254 T. Ohyama et al. / FEBS Letters 572 (2004) 251–255was SRVEVSKVLILGSGGLSIGQAGEFDYSGSQAV- and
was the same as the amino acid sequence at positions 418–449
from rat CPS I [18]. When the puriﬁed GABA[arrow beta]A-
laAT convertase was incubated with the antiserum against rat
liver CPS I, GABA[arrow beta]AlaAT convertase activity was
inhibited with an antiserum dose dependency (Fig. 2). The
puriﬁed CPS I (30 lg) did not show any sign of GABA[arrow
beta]AlaAT convertase activity under the standard assay
conditions.
After incubation of the puriﬁed rat brain mature-GABA AT
with GABA[arrow beta]AlaAT convertase (Fig. 2, lane 1), the
product molecular mass was 52 960 Da by MALDI-TOF MS,
which was the same as that of rat liver b-AlaAT I [10].
3.3. Expression of recombinant GABA[arrow beta]AlaAT
convertase
In order to estimate whether the recombinant peptide is
responsible for the GABA[arrow beta]AlaAT convertase ac-
tivity, an expression vector containing the coding region of the
418–1305 peptide fragment of rat CPS 1 was constructed and
transfected into NIH3T3 cells. Fig. 3A shows that the re-
combinant peptide was detected in NIH3T3 cells transfected
with pCI-neo-convertase vector, but not empty pCI-neo vec-
tor. The recombinant protein revealed the GABA[arrow be-
ta]AlaAT convertase activity (Fig. 3B, lanes 2, 3). The extractFig. 3. GABA[arrow beta]AlaAT convertase activity of the re-
combinant CPS I418–1305. (A) Immunoblot analysis of recombinant
GABA[arrow beta]AlaAT convertase with CPS I antibody. Lane 1, 50
lg protein of crude extract of NIH3T3 cells which were transfected
with the pCI-neo vectors; lane 2, 50 lg protein of crude extract of
NIH3T3 cells which were transfected with the pCI-neo-convertase.
(B) GABA[arrow beta]AlaAT convertase activity. GABA[arrow be-
ta]AlaAT convertase activity of each sample was assayed. Lane 1,50 lg
protein of NIH3T3 cells transfected with the pCI-neo vector; lane 2, 50
lg protein of crude extract of NIH3T3 cells transfected with the pCI-
neo-convertase; lane 3, 20 lg protein of crude extract of NIH3T3 cells
transfected with the pCI-neo-convertase.from the control cells did not show any sign of enzyme activity
(Fig. 3B, lane 1).
3.4. Processing of b-AlaAT I precursor by GABA[arrow
beta]AlaAT convertase
The recombinant b-AlaAT I precursors were utilized to con-
ﬁrm the processing properties of GABA[arrow beta]AlaAT
convertase. The pre-GABAATandmature-GABAATat 1–500
and 28–500, respectively, in Scheme 1, were expressed in E. coli.
The puriﬁed GABA[arrow beta]AlaAT convertase cleaves ma-
ture-GABA AT (Fig. 4, lane 6), but not the pre-GABA AT as a
substrate (Fig. 4, lane 4). The band of b-AlaAT I in Fig. 4, lane 6
was analyzed using Edman degradation. The N-terminal se-
quence was VDFEFDY-, which was the same as the N-terminal
amino acid sequence of the liver-type mature-b-AlaAT I.4. Discussion
We puriﬁed a new type of mature-b-AlaAT I converting
endopeptidase, GABA[arrow beta]AlaAT convertase, from rat
livers. Most mitochondrial proteins are translated on cyto-
plasmic ribosomes as larger precursors and are then imported
into the organelle [19,20]. The presequences are recognized so
as to direct the proteins to mitochondria, then cleaved and lost
in the mitochondria [21,22]. The mitochondrial presequences
were cleaved and classiﬁed as four cleavage site motifs as
reported by Gakh et al. [23]: (i) XRX#X(S/X) (R-2 motif);
(ii) XRX(Y/X)#(S/A/X)X (R-3 motif); (iii) XRX#(F/L/I)XX(S/
T/G)XXXX# (R-10 motif); and (iv) XX#X(S/X) (R-none
motif). The amino acid sequence of the coding region of rat
GABA AT (b-AlaAT I) contains 500 residues [13] similar to
GABA AT from pig [24] and human [25]. Precursors of GABA
AT from pig and human have the R-10 motif, but that of rat
has the R-2 motif (Scheme 1). Therefore, the mature-GABA
AT from pig [24,26] or human [25] was composed of the same
472 amino acid residues, while the mature one from rat [10]
was 473. The N-terminal amino acids of b-AlaAT I from rat
liver and GABA AT from rat brain are Val [6] and I1e [11],
respectively. The N-terminal of rat mature-GABA AT may be
further cleaved in the liver (Scheme 1). It was suggested that a
new type of liver mature-b-AlaAT I converting endopeptidase,
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tide at the N-terminal of the brain form of GABA AT [10]. The
puriﬁed GABA[arrow beta]AlaAT convertase could not cleave
the rat pre-GABA AT, which is expressed in E. coli, but was
active for expressed rat mature-GABA AT. We conﬁrmed the
previous ﬁnding that the mature-b-AlaAT I is proteolytically
cleaved in two steps [10]. The ﬁrst cleavage of the R-2 motif is
performed by a mitochondrial processing peptidase, yielding
an intermediate sized protein which is the mature GABA AT.
The second cleavage is carried out by a mitochondrial endo-
peptidase of GABA[arrow beta]AlaAT convertase.
The N-terminal amino acid sequences of GABA[arrow be-
ta]AlaAT convertase were the same as positions 418–449 of rat
liver CPS I. The subunit molecular mass of GABA[arrow be-
ta]AlaAT convertase was 97 652 Da. The subunit molecular
mass of rat liver CPS I is 160 kDa [18]. The precursor of CPS I
consists of a 1500 amino acid residue with a 38-amino-termmal
leader segment. Southern hybridization analysis of rat genomic
DNA suggested that the CPS I gene is present in a single copy
[18]. These ﬁndings suggest that CPS I may be cleaved between
positions 417/418 and 1305/1306 (theoretical molecular mass
97 652 Da).
After the total RNA of rat liver was translated in a rabbit
reticulocyte protein-synthesizing-system, the protein CPS I
produced was detected as a single band by CPS I antibody
[14,15]. Immunoblot analysis with anti-rat CPS I rabbit serum
showed a single band with the same positive stain using
Coomassie brilliant blue R-250 (Fig. 1D). These ﬁndings
suggest that GABA[arrow beta]AlaAT convertase is composed
of a 98 kDa protein cleaved from CPS I. The 98 kDa protein
stained with anti-rat CPS I rabbit serum was found in the rat
liver mitochondrial extract (Fig. 1A). The peptide CPS I 418–
1305 expressed in NIH3T3 cells shows the GABA[arrow be-
ta]AlaAT convertase activity (Fig. 3). It is well established that
CPS I is not distributed in the brain. Therefore, liver-type
b-AlaAT I cannot be detected in the brain (Fig. 4, lane 1).
The signiﬁcance of the existence of GABA[arrow beta]A-
laAT convertase is not well documented. Pyrimidine catabo-
lizing enzymes of dihydropyrimidine dehydrogenase,
dihydropyrimidinase and b-ureidopropionase are localized
mainly in the liver, followed by the kidney in rats [10]. The
aﬃnity of b-alanine for b-AlaAT I is signiﬁcantly higher than
that for GABA AT in rats [10]. The b-alanine concentration is
about 0.1 mM in the liver [27] and 0.01–0.04 mM in the brain
[28,29], Therefore, liver-type mature-b-AlaAT I may be more
favorable for b-alanine catabolism than brain-type mature-
GABA AT at least.
GABA[arrow beta]AlaAT convertase derived from CPS I
was clearly found in the rat liver mitochondrial extract and it is
not formed during the course of the puriﬁcation steps. CPS I in
the rat liver has been estimated to make up 15–20% of the total
mitochondrial protein [30]. It is well recognized that CPS I
functions to convert ammonia, bicarbonate and ATP into
carbamoyl phosphate, the initial step in the urea cycle. Native
CPS I did not show the GABA[arrow beta]AlaAT convertaseactivity. As shown in this paper, a fragment of CPS I had an
unexpected proteolytic activity and processing activity func-
tion towards rat liver b-AlaAT I.References
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